Paolo Pucci offers Chiesi a wealth of governance experience, having served as a CEO, independent director, and committee member across entities in the US, EU, and Brazil.

He has served as Non-Executive Director on multiple boards, including Trillium Therapeutics Inc. (NASDAQ:TRIL, acquired by Pfizer in 2021), New Link Genetics Inc, Algeta ASA (Oslo Borse:ALGETA, acquired by Bayer AG in 2014), Dyax Inc. (NASDAQ:DYAX, acquired by Shire in 2016) and currently serves as an independent director Replimune Group Inc. (NASDAQ:REPL), Merus NV (NASDAQ:MRUS) and as Lead Independent Director at West Pharmaceutical Services (NYSE:WST).

Pucci started his career in industrial chemicals, auditing, and then banking. He worked as Indirect Sales and Marketing Manager at Citibank in Italy, a role he left in 1991.

He then pivoted to work in pharma and from 1991 and 2001, Pucci took various roles at Eli Lilly & Company Inc. beginning in Italy and subsequently US, France and Sweden. His positions included Marketing Head Central Nervous System for Europe Middle East Africa region, National Sales Manager Diabetology and Endocrinology, and Business Unit Manager Neuroscience. He finished his time at Eli Lilly as Country Head, Sweden.

Between2001 and2008, Pucci took on various roles at Bayer Schering AG, including serving as Country Head Pharmaceuticals Italy and subsequently and simultaneously as a member of the Board of Management Global Pharma, SVP North America Pharma and President Global Specialty Pharmaceuticals. He ended his time at Bayer Schering as SVP and President of the Global Specialty Pharmaceuticals Business Unit based in the U.S.

Between2008 and 2020, he was the Chief Executive Officer of ArQule. In this role, Pucci successfully raised approximately $400 million in capital and restructured the company, balancing discovery and clinical development.

He led the development of a proprietary clinical pipeline featuring several best-in-class compounds in oncology and rare diseases, culminating in the company's sale to Merck (NYSE:MSD) for $2.7 billion in2020.

Paolo Pucci graduated from the Università di Napoli, Italy, with a BA in Economics, 1984 and in 1985 obtained license to practice as Dottore Commercialista (Chartered Accountant) in Italy. He finished his studies graduating from the University of Chicago Booth Graduate School of Business with an MBA in 1990. He holds dual American and Italian citizenships.